 | • レポートコード：MRC2212A139 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、258ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に4,294.85百万ドルであった世界の自己免疫疾患診断市場規模が、2022年に4,672.36百万ドルへと拡大し、2027年までにCAGR 8.91％で成長して7,169.73百万ドルに達すると予測しています。当書は、自己免疫疾患診断の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、疾患別（アジソン病、セリアック病、皮膚筋炎、バセドウ病、その他）分析、検査別（自己抗体＆免疫学的検査、炎症マーカー検査、定期的臨床検査）分析、製品別（消耗品＆アッセイキット、診断用機器）分析、エンドユーザー別（臨床検査室、病院）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの内容をまとめております。なお、当書に掲載されている企業情報には、Abbott Laboratories、AESKU.GROUP GmbH & Co. KG、AstraZeneca PLC、Beckman Coulter, Inc.、Bio-Rad Laboratories, Inc.、BioAgilytix Labs、Biogenuix Medsystems Private Limited、bioMerieux SA、EUROIMMUN Medical Laboratory Diagnostics AGなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の自己免疫疾患診断市場規模：疾患別 - アジソン病における市場規模 - セリアック病における市場規模 - 皮膚筋炎における市場規模 - バセドウ病における市場規模 - その他疾患における市場規模 ・世界の自己免疫疾患診断市場規模：検査別 - 自己抗体＆免疫学的検査の市場規模 - 炎症マーカー検査の市場規模 - 定期的臨床検査の市場規模 ・世界の自己免疫疾患診断市場規模：製品別 - 消耗品＆アッセイキットの市場規模 - 診断用機器の市場規模 ・世界の自己免疫疾患診断市場規模：エンドユーザー別 - 臨床検査室における市場規模 - 病院における市場規模 ・世界の自己免疫疾患診断市場規模：地域別 - 南北アメリカの自己免疫疾患診断市場規模 アメリカの自己免疫疾患診断市場規模 カナダの自己免疫疾患診断市場規模 ブラジルの自己免疫疾患診断市場規模 ... - アジア太平洋の自己免疫疾患診断市場規模 日本の自己免疫疾患診断市場規模 中国の自己免疫疾患診断市場規模 インドの自己免疫疾患診断市場規模 韓国の自己免疫疾患診断市場規模 台湾の自己免疫疾患診断市場規模 ... - ヨーロッパ/中東/アフリカの自己免疫疾患診断市場規模 イギリスの自己免疫疾患診断市場規模 ドイツの自己免疫疾患診断市場規模 フランスの自己免疫疾患診断市場規模 ロシアの自己免疫疾患診断市場規模 ... - その他地域の自己免疫疾患診断市場規模 ・競争状況 ・企業情報 |
The Global Autoimmune Disease Diagnostics Market size was estimated at USD 4,294.85 million in 2021 and expected to reach USD 4,672.36 million in 2022, and is projected to grow at a CAGR 8.91% to reach USD 7,169.73 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Autoimmune Disease Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Localized Autoimmune Disease Diagnostics and Systemic Autoimmune Disease Diagnostics.
Based on Indication, the market was studied across Addison Disease, Celiac Disease, Dermatomyositis, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Reactive Arthritis, Rheumatoid Arthritis, Sjögren syndrome, Systemic Lupus Erythematosus, and Type I Diabetes.
Based on Test, the market was studied across Autoantibodies & Immunologic Test, Inflammatory Marker, and Routine Laboratory Test. The Autoantibodies & Immunologic Test is further studied across Anti-cyclic Citrullinated Peptide, Antinuclear Antibody, C-reactive Protein, Erythrocyte Sedimentation Rate, Rheumatoid Factor, and Thyroid Antibody Tests. The Thyroid Antibody Tests is further studied across T3, T3RU, T4, and TSH.
Based on Product, the market was studied across Consumable & Assay Kit and Diagnostic Instrument.
Based on End User, the market was studied across Clinical Laboratory and Hospital.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Autoimmune Disease Diagnostics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Autoimmune Disease Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Autoimmune Disease Diagnostics Market, including Abbott Laboratories, AESKU.GROUP GmbH & Co. KG, AstraZeneca PLC, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, Biogenuix Medsystems Private Limited, bioMerieux SA, EUROIMMUN Medical Laboratory Diagnostics AG, Exagen Inc., F. Hoffmann-La Roche AG, Hemagen Diagnostics, Inc., Novartis AG, Pfizer Inc., Quest Diagnostics, Sanofi S.A., SD BioSensor Inc., Siemens Healthineers AG, SQI Diagnostics, Thermo Fisher Scientific Inc., Trinity Biotech PLC, and Werfen Group.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Autoimmune Disease Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Autoimmune Disease Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Autoimmune Disease Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Autoimmune Disease Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Autoimmune Disease Diagnostics Market?
6. What is the market share of the leading vendors in the Global Autoimmune Disease Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Autoimmune Disease Diagnostics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Incidence of Autoimmune Diseases such as Rheumatoid Arthritis, Graves’ disease and Hashimoto’s thyroiditis
5.1.1.2. Awareness Among Public About Autoimmune Diseases and Favorable Government Initiatives
5.1.1.3. Improved Laboratory Techniques and Automation
5.1.2. Restraints
5.1.2.1. High Frequency of False Positive Results
5.1.2.2. Slow Turnaround Time for Diagnostic Test
5.1.3. Opportunities
5.1.3.1. Adoption of Biosensors for Autoimmune Disease Diagnosis
5.1.3.2. Strategic Partnerships Between Physicians and Clinical Laboratories
5.1.3.3. Potential Growth in Reagent Rental Agreements and Collaboration Activities
5.1.4. Challenges
5.1.4.1. Cost associated with the diagnosis process
5.2. Cumulative Impact of COVID-19
6. Autoimmune Disease Diagnostics Market, by Type
6.1. Introduction
6.2. Localized Autoimmune Disease Diagnostics
6.3. Systemic Autoimmune Disease Diagnostics
7. Autoimmune Disease Diagnostics Market, by Indication
7.1. Introduction
7.2. Addison Disease
7.3. Celiac Disease
7.4. Dermatomyositis
7.5. Graves Disease
7.6. Hashimoto Thyroiditis
7.7. Multiple Sclerosis
7.8. Myasthenia Gravis
7.9. Pernicious Anemia
7.10. Reactive Arthritis
7.11. Rheumatoid Arthritis
7.12. Sjögren syndrome
7.13. Systemic Lupus Erythematosus
7.14. Type I Diabetes
8. Autoimmune Disease Diagnostics Market, by Test
8.1. Introduction
8.2. Autoantibodies & Immunologic Test
8.3.1. Anti-cyclic Citrullinated Peptide
8.3.2. Antinuclear Antibody
8.3.3. C-reactive Protein
8.3.4. Erythrocyte Sedimentation Rate
8.3.5. Rheumatoid Factor
8.3.6. Thyroid Antibody Tests
8.3.7.1. T3
8.3.7.2. T3RU
8.3.7.3. T4
8.3.7.4. TSH
8.3. Inflammatory Marker
8.4. Routine Laboratory Test
9. Autoimmune Disease Diagnostics Market, by Product
9.1. Introduction
9.2. Consumable & Assay Kit
9.3. Diagnostic Instrument
10. Autoimmune Disease Diagnostics Market, by End User
10.1. Introduction
10.2. Clinical Laboratory
10.3. Hospital
11. Americas Autoimmune Disease Diagnostics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Autoimmune Disease Diagnostics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Autoimmune Disease Diagnostics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. Abbott Laboratories
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. AESKU.GROUP GmbH & Co. KG
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. AstraZeneca PLC
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Beckman Coulter, Inc.
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Bio-Rad Laboratories, Inc.
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. BioAgilytix Labs
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Biogenuix Medsystems Private Limited
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. bioMerieux SA
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. EUROIMMUN Medical Laboratory Diagnostics AG
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Exagen Inc.
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. F. Hoffmann-La Roche AG
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Hemagen Diagnostics, Inc.
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Novartis AG
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Pfizer Inc.
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Quest Diagnostics
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Sanofi S.A.
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. SD BioSensor Inc.
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. Siemens Healthineers AG
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
15.19. SQI Diagnostics
15.19.1. Business Overview
15.19.2. Key Executives
15.19.3. Product & Services
15.20. Thermo Fisher Scientific Inc.
15.20.1. Business Overview
15.20.2. Key Executives
15.20.3. Product & Services
15.21. Trinity Biotech PLC
15.21.1. Business Overview
15.21.2. Key Executives
15.21.3. Product & Services
15.22. Werfen Group
15.22.1. Business Overview
15.22.2. Key Executives
15.22.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing